SCHEMBL18486227

SCHEMBL18486227

COc1ccc(C(OC[C@H]2O[C@@H](n3cnc4c(-c5cccc(CO)c5)ncnc43)C[C@@H]2O[Si](C)(C)C(C)(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TYMP P19971 6/20 0.42
DNPH1 O43598 9/20 0.41
ADORA1 P30542 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486389 0.92 TYMP (0.42) TYMPDNPH1ADORA1
SCHEMBL18486322 0.90 TYMP (0.41) TYMPDNPH1ADORA1
SCHEMBL18486324 0.89 TYMP (0.40) TYMPDNPH1ADORA1
SCHEMBL24191239 0.84 ADORA1 (0.49) TYMPADORA1
SCHEMBL18486221 0.84 TYMP (0.54) TYMPADORA1
SCHEMBL18486323 0.84 TYMP (0.54) TYMPDNPH1ADORA1
SCHEMBL18486261 0.82 TYMP (0.56) TYMPDNPH1ADORA1
SCHEMBL18486223 0.81 TYMP (0.43) TYMPADORA1
SCHEMBL18486299 0.81 TYMP (0.52) TYMPDNPH1
SCHEMBL17911711 0.81 TYMP (0.45) TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 TYMP 120/4885DNPH1 2051/4885ADORA1 529/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 TYMP 121/4885DNPH1 2035/4885ADORA1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.